comparemela.com

Latest Breaking News On - European association for haemophilia - Page 8 : comparemela.com

Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in . Spark Therapeutics, Inc.February 5, 2021 GMT Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X10 11 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable factor VIII (FVIII) expression at greater than 52 weeks Data show 98-percent reduction in annualized infusion rate (AIR) and 85-percent reduction in annualized bleed rate (ABR) after a follow up of between 15 and 18 months or 5.5 total patient years

Freeline to Present Data at the 2021 Virtual Congress of the European Association for

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Freeline to Present Data at the 2021 Virtual Congress of the European Association for . Freeline TherapeuticsJanuary 26, 2021 GMT LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021. In addition, the Company will present data on its gene therapy programmes for Gaucher and Fabry Disease, in one oral platform presentation and three e-posters at the 17TH Annual WORLD

Octapharma to Demonstrate Ongoing Commitment to Improving the Long-term Health of People With Haemophilia A at the 14th EAHAD Annual Congress

Share: Octapharma announced today a satellite symposium and poster presentation at the 14th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which will be held virtually from February 3–5, 2021. The satellite symposium, A family journey with Nuwiq ®: Early treatment decisions for long-term health, will be chaired by Dr Robert F. Sidonio Jr. (Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Children s Healthcare of Atlanta, Emory University, Atlanta, USA) and will follow the treatment journey of a family with two sons diagnosed with severe haemophilia A. Speakers will address key treatment decisions and considerations for long-term health, including prevention and treatment of bleeds, inhibitor risk, inhibitor eradication, and bone and joint health, in the context of the evolving haemophilia A treatment landscape. The symposium will be available via the EAHAD online platform on February 4, 2021, at 18:00 CET.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.